News

The U.S. Food and Drug Administration (FDA) has approved inebilizumab as a treatment for generalized myasthenia gravis (gMG). The newly approved therapy, which developer Amgen will market under the brand name Uplizna, is specifically indicated for adults with gMG who are positive for antibodies targeting the acetylcholine…

For people with generalized myasthenia gravis (MG) in the U.S., getting a correct diagnosis is often a difficult and stressful process that can take more than two years from the time of symptom onset, a study showed. Findings suggest that people with MG often feel dismissed by doctors when…

The Myasthenia Gravis Foundation of America (MGFA) has published a new resource designed to help people with myasthenia gravis (MG) understand the medical jargon and terminology that’s commonly used to discuss the disease. The MG Lexicon offers succinct definitions for a wide range of terms. The definitions…

Blood levels of five proteins involved in the body’s inflammatory response may be used to diagnose myasthenia gravis (MG) and distinguish it from other autoimmune diseases, according to new research findings from scientists working in Sweden and Germany. The research team also identified other small sets of inflammatory proteins…

Imaavy (nipocalimab) has been approved in the European Union as an add-on to standard of care treatment for adults and adolescents, ages 12 and older, with generalized myasthenia gravis (gMG) and self-reactive antibodies targeting the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). The decision by the European Commission makes…

An enzyme, called S-1117, can disarm self-reactive immunoglobulin G (IgG) antibodies targeting the acetylcholine receptor (AChR) that drive most cases of myasthenia gravis (MG), according to a study that used blood samples from patients. “This study presents S-1117, an IgG-specific protease [a protein-degrading enzyme], as a promising therapeutic approach…

Note: This story was updated Nov. 26, 2025, to correct that the cladribine formulation being tested as a potential gMG treatment differs from the one used in Mavenclad, an approved therapy for multiple sclerosis. The U.S. Food and Drug Administration (FDA) has granted fast track designation to cladribine, an…

In Japan, myasthenia gravis (MG) was associated with an older age at onset and better clinical outcomes in 2018 compared with 2006, according to a new analysis of nationwide survey data spanning 12 years. Data also showed a reduction over time in the doses of corticosteroids, anti-inflammatory steroid…

The first patient has been enrolled in a myasthenia gravis (MG) registry to collect clinical information from real-world settings across the U.S., with the aim of better understanding the disease and ultimately improving care. Thermo Fisher Scientific’s newly launched registry is recruiting people with the ocular and generalized…

Results from an ongoing Phase 1/2 clinical trial testing Cabaletta Bio‘s experimental cell therapy rese-cel (resecabtagene autoleucel) in adults with myasthenia gravis (MG) are expected in the second half of 2026. That’s according to a press release from Cabaletta, where the company reported its latest financial and…